Background/Aims: Supplementation of n–3 long-chain polyunsaturated fatty acids (LCPUFA) is considered as adjuvant therapy in acute pancreatitis. We investigated plasma fatty acid status in chronic pancreatitis (CP). Methods: Patients with alcoholic CP (n = 56, gender: 33/23 male/female, age: 60.0 [14.0] years (median [IQR]), who reported giving up alcohol consumption several years ago and 51 control subjects were included into the study. The fatty acid composition of plasma phospholipids (PL), triacylglycerols (TG) and sterol esters (STE) was analyzed. Results: The sum of monounsaturated fatty acids was significantly higher in patients with CP than in controls (PL: 12.83 [3.35] vs. 12.20 [1.95], TG: 40.51 [6.02] vs. 37.52 [5.80], STE: 20.58 [7.22] vs. 17.54 [3.48], CP vs. control, % weight/weight, median [IQR], p < 0.05). Values of arachidonic acid were significantly lower in patients with CP than in controls (PL: 10.57 [3.56] vs. 11.66 [3.25], STE: 8.14 [2.63] vs. 9.24 [2.86], p < 0.05). Values of eicosapentaenoic acid and docosahexaenoic acid did not differ and there was no difference in the ratio of n–3 to n–6 LCPUFA. Conclusion: Our present data do not furnish evidence for the supplementation of n–3 LCPUFA to the diet of CP patients in relatively good clinical condition.

1.
Witt H, Apte MV, Keim V, Wilson JS: Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 2007;132:1557–1573.
2.
Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, Folkerts G, Friedmann PS, Frost GS, Guarner F, Løvik M, Macfarlane S, Meyer PD, M’Rabet L, Serafini M, van Eden W, van Loo J, Vas Dias W, Vidry S, Winklhofer-Roob BM, Zhao J: Inflammatory disease processes and interactions with nutrition. Br J Nutr 2009;101 (suppl 1):S1–S45.
3.
Calder PC: Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009;91:791–795.
4.
Sztefko K, Panek J: Serum free fatty acid concentration in patients with acute pancreatitis. Pancreatology 2001;1:230–236.
5.
Lasztity N, Hamvas J, Biro L, Nemeth E, Marosvolgyi T, Decsi T, Pap A, Antal M: Effect of enterally administered n–3 polyunsaturated fatty acids in acute pancreatitis – a prospective randomized clinical trial. Clin Nutr 2005;24:198–205.
6.
Wang X, Li W, Li N, Li J: Omega–3 fatty acids-supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: a randomized and controlled study. JPEN J Parenter Enteral Nutr 2008;32:236–241.
7.
Wang X, Li W, Zhang F, Pan L, Li N, Li J: Fish oil-supplemented parenteral nutrition in severe acute pancreatitis patients and effects on immune function and infectious risk: a randomized controlled trial. Inflammation 2009;32:304–309.
8.
Petrov MS, Atduev VA, Zagainov VE: Advanced enteral therapy in acute pancreatitis: is there a room for immunonutrition? A meta-analysis. Int J Surg 2008;6:119–124.
9.
Foitzik T, Eibl G, Schneider P, Wenger FA, Jacobi CA, Buhr HJ: Omega–3 fatty acid supplementation increases anti-inflammatory cytokines and attenuates systemic disease sequelae in experimental pancreatitis. JPEN J Parenter Enteral Nutr 2002;26:351–356.
10.
Marek PE: What is the best way to feed patients with pancreatitis? Curr Opin Crit Care 2009;15:131–138.
11.
Weylandt KH, Nadolny A, Kahlke L, Kohnke T, Schmocker C, Wang J, Lauwers GY, Glickman JN, Kang JX: Reduction of inflammation and chronic tissue damage by omega–3 fatty acids in fat-1 transgenic mice with pancreatitis. Biochim Biophys Acta 2008;1782:634–641.
12.
Nakamura T, Takebe K, Imamura K, Arai Y, Kudoh K, Terada A, Ishii M, Yamada N, Tandoh Y, Machida K: Changes in plasma fatty acid profile in Japanese patients with chronic pancreatitis. J Int Med Res 1995;23:27–36.
13.
Quilliot D, Walters E, Bohme P, Lacroix B, Bonte JP, Fruchart JC, Drouin P, Duriez P, Ziegler O: Fatty acid abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus. Eur J Clin Nutr 2003;57:496–503.
14.
Decsi T, Szabo E, Burus I, Marosvolgyi T, Kozari A, Erhardt E, Soltesz G: Low contribution of n–3 polyunsaturated fatty acids to plasma and erythrocyte membrane lipids in diabetic young adults. Prostaglandins Leukot Essent Fatty Acids 2007;76:159–164.
15.
Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, Beger HG: Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002;25:26–30.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.